Genentech has reported in the Proceedings of the National Academy of Sciences that a variant of its Activase (t-PA) thrombolytic, TNK-t-PA, has shown advantages over the standard Activase drug in dissolving blood clots.
The company said that in animal models the product dissolved 50% of blood clots in about one-third the time required by standard Activase infusion. The drug was also retained in the blood stream about eight times longer than Activase. Because of its slower clearance and faster clot dissolution activity, notes the company, it offers the potential to be an effective thrombolytic given as an intravenous bolus at a relatively low dose. The company expects Phase I clinical trials to begin in early 1995.
In addition, the firm reported the completion of Phase I trials of its anti-IgE humanized monoclonal antibody for treating allergic rhinitis. In the past week, Genentech has begun a Phase II clinical trial for the product in this indication. Phase I trials for the treatment of asthma are ongoing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze